Clinical Trial Update: A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 first-in-human study of GSK3352589 (a RET tyrosine kinase inhibitor) in healthy volunteers; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• GSK3352589 (GSK3352589)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Irritable Bowel Syndrome | Phase 1 | Status: COMPLETED | Results posted: 2019-08-09